PRTO vs. ALGS, GNTA, TSBX, IKNA, ENTX, CDTX, TIL, CRTX, ELUT, and CGTX
Should you be buying Proteon Therapeutics stock or one of its competitors? The main competitors of Proteon Therapeutics include Aligos Therapeutics (ALGS), Genenta Science (GNTA), Turnstone Biologics (TSBX), Ikena Oncology (IKNA), Entera Bio (ENTX), Cidara Therapeutics (CDTX), Instil Bio (TIL), Cortexyme (CRTX), Elutia (ELUT), and Cognition Therapeutics (CGTX). These companies are all part of the "medical" sector.
Aligos Therapeutics (NASDAQ:ALGS) and Proteon Therapeutics (NASDAQ:PRTO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk, valuation, dividends and media sentiment.
Proteon Therapeutics received 249 more outperform votes than Aligos Therapeutics when rated by MarketBeat users. Likewise, 69.21% of users gave Proteon Therapeutics an outperform vote while only 62.16% of users gave Aligos Therapeutics an outperform vote.
60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 23.0% of Proteon Therapeutics shares are held by institutional investors. 16.5% of Aligos Therapeutics shares are held by insiders. Comparatively, 45.7% of Proteon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Proteon Therapeutics has a net margin of 0.00% compared to Proteon Therapeutics' net margin of -607.03%. Aligos Therapeutics' return on equity of 0.00% beat Proteon Therapeutics' return on equity.
Aligos Therapeutics has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500. Comparatively, Proteon Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.
In the previous week, Proteon Therapeutics' average media sentiment score of 0.00 equaled Aligos Therapeutics'average media sentiment score.
Proteon Therapeutics has lower revenue, but higher earnings than Aligos Therapeutics. Proteon Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Proteon Therapeutics beats Aligos Therapeutics on 7 of the 12 factors compared between the two stocks.
Get Proteon Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Proteon Therapeutics Competitors List
Related Companies and Tools
